Results 71 to 80 of about 78,276 (237)

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens, Dirk Jan A. R. Moes, Yanick Boer, Aiko P. J. de Vries, Dorottya K. de Vries, Danny van der Helm, Soufian Meziyerh, Dave L. Roelen, Stefan Böhringer, Teun Van Gelder, Jesse J. Swen   +10 more
wiley   +1 more source

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]

Journal of Medical Biochemistry, 2020
Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana, Kotur Nikola, Gašić Vladimir, Klaassen Kristel, Ristivojević Bojan, Stojiljković Maja, Pavlović Sonja, Zukić Branka   +7 more
doaj  

Building a Pharmacogenomics Knowledge Model Toward Precision Medicine: Case Study in Melanoma

JMIR Medical Informatics, 2020
BackgroundMany drugs do not work the same way for everyone owing to distinctions in their genes. Pharmacogenomics (PGx) aims to understand how genetic variants influence drug efficacy and toxicity.
Kang, Hongyu, Li, Jiao, Wu, Meng, Shen, Liu, Hou, Li   +4 more
doaj   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion. [PDF]

, 2017
INTRODUCTION:The perioperative pain experience shows great interindividual variability and is difficult to predict. The mu-1 opioid receptor gene (OPRM1) is known to play an important role in opioid-pain pathways.
Chidambaran, Vidya, Ding, Lili, Geisler, Kristie, Ji, Hong, Martin, Lisa J, Sadhasivam, Senthilkumar, Stubbeman, Bobbie L, Weirauch, Matthew T, Zhang, Xue   +8 more
core   +1 more source

Supplementary Table S2 from Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors [PDF]

, 2023
Richard D. Baird, Jos Kitzen, Paul A. Clarke, André Planting, Sarah Reade, Alison Reid, Lyndsey Welsh, Luis López Lázaro, Begoña de las Heras, Ian Judson, Stan B. Kaye, Ferry A.L.M. Eskens, Paul Workman, Johann S. de Bono, Jaap Verweij   +14 more
openalex   +1 more source

PharmVar GeneFocus: NAT2—Genetic Variation and Updated Nomenclature

Clinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 (NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines.
Georgia Papanikolaou, Estella S. Poloni, José A.G. Agúndez, Raquel L.F. Teixeira, Erin C. Boone, Adalberto Rezende Santos, Michelle Whirl‐Carrillo, Katrin Sangkuhl, Teri E. Klein, Mariam R. Habil, Giannoulis Fakis, Rodney F. Minchin, David W. Hein, Sotiria Boukouvala, Andrea Gaedigk   +14 more
wiley   +1 more source

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. [PDF]

, 2014
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of resistance, and ongoing studies ...
Hurvitz, Sara A, Olevsky, Olga, Sadeghi, Saeed   +2 more
core   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source